Galenica AG/€GALE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Galenica AG
Galenica AG is a healthcare company based in Switzerland, with a core focus on the health and pharmacy sector. The company operates through two main segments: Health & Beauty and Services. The Health & Beauty segment includes the operation of pharmacies and the distribution of health products, while the Services segment provides logistics and related services for the Swiss healthcare sector. Founded in 1927, Galenica has evolved to become a key player in the Swiss market with a comprehensive network and infrastructure that facilitate efficient healthcare distribution. Its strategic positioning is enhanced by its extensive logistics capabilities and strong presence within Switzerland, headquartered in Bern.
- Ticker
- €GALE
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 6,623
- Headquarters
- Bern, Switzerland
- Website
- www.galenica.com
Galenica AG Metrics
BasicAdvanced
€4.8B
27.58
€3.46
0.28
€2.71
1.42%
Price and volume
Market cap
€4.8B
Beta
0.28
52-week high
€105.30
52-week low
€86.15
Average daily volume
84K
Dividend rate
€2.71
Financial strength
Current ratio
1.07
Quick ratio
0.642
Long term debt to equity
0.54
Total debt to equity
0.783
Dividend payout ratio (TTM)
78.72%
Interest coverage (TTM)
13.90%
Profitability
EBITDA (TTM)
277.767
Gross margin (TTM)
12.46%
Net profit margin (TTM)
3.71%
Operating margin (TTM)
4.77%
Effective tax rate (TTM)
17.18%
Revenue per employee (TTM)
€706,110
Management effectiveness
Return on assets (TTM)
4.00%
Return on equity (TTM)
11.36%
Valuation
Price to earnings (TTM)
27.584
Price to revenue (TTM)
1.023
Price to book
3.11
Price to tangible book (TTM)
-245.42
Price to free cash flow (TTM)
22.95
Free cash flow yield (TTM)
4.36%
Free cash flow per share (TTM)
4.162
Dividend yield (TTM)
2.84%
Forward dividend yield
1.42%
Growth
Revenue change (TTM)
6.39%
Earnings per share change (TTM)
-17.39%
3-year revenue growth (CAGR)
5.09%
3-year earnings per share growth (CAGR)
-16.06%
3-year dividend per share growth (CAGR)
4.35%
Bulls say / Bears say
Sales rose 5.7% in the first nine months of 2026, and Galenica reaffirmed its full-year targets of 5–7% sales growth and 6–8% adjusted EBIT growth. This points to continued growth despite a slower wholesale quarter. (Galenica)
Pharmacy sales grew 6.2% in the first nine months, with organic growth of 4.5% and further market-share gains. Paid pharmacy health services also grew 26%, adding a developing source of customer demand. (Galenica)
Home care and diagnostics are adding growth beyond the pharmacy network: Galenica reported continued progress in both areas, with diagnostics sales reaching CHF 91.6 million in the first nine months. Combining home-care operations and linking laboratory services with Galexis could support further development of these businesses. (Galenica)
Products & Brands sales fell 7.2% in the first nine months, as a weak consumer-health market hurt Verfora and regulatory-related inventory reductions weighed on Perskindol. This shows Galenica’s branded-products business remains exposed to seasonal demand and international disruption. (Galenica)
Galenica plans to close Bichsel’s pharmaceutical production because the business is not competitive, with up to 170 jobs affected. The closure brings special costs, and reported first-half EBIT and net profit fell sharply, although management lowered its full-year cost estimate to CHF 30 million. (Galenica, SWI swissinfo.ch)
Regulatory changes may squeeze margins in diagnostics and home care: Galenica reported 10% price cuts on its ten highest-revenue laboratory tests, while the 2027 artificial-nutrition reimbursement model will reduce product margins and its service payment is still being defined. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
Upcoming events
No upcoming events
Funds containing Galenica AG
AllUSDEURGBP
Fund name | Fund size | €GALE weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.33% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.33% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.05% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.05% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.